thalidomide has been researched along with Hypertension, Pulmonary in 11 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thalidomide has been associated with an increased risk of thromboembolic pulmonary hypertension (PH)." | 7.74 | Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. ( Barbetakis, N; Bischiniotis, T; Lafaras, C; Mandala, E; Platogiannis, D; Verrou, E; Zervas, K, 2008) |
| "Primary plasma cell leukemia (PPCL) is a rare disease that progresses rapidly." | 5.40 | Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension. ( Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S, 2014) |
| "As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide." | 5.36 | Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. ( de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E, 2010) |
| " Thalidomide has been associated with an increased risk of thromboembolic pulmonary hypertension (PH)." | 3.74 | Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. ( Barbetakis, N; Bischiniotis, T; Lafaras, C; Mandala, E; Platogiannis, D; Verrou, E; Zervas, K, 2008) |
| "POEMS syndrome is a clonal plasma cell disease characterized by polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes." | 2.49 | New advances in the diagnosis and treatment of POEMS syndrome. ( Li, J; Zhou, DB, 2013) |
| "Primary plasma cell leukemia (PPCL) is a rare disease that progresses rapidly." | 1.40 | Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension. ( Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S, 2014) |
| "Echocardiography detected left ventricular hypertrophy and diastolic dysfunction." | 1.39 | Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome. ( Hisa, S; Kanno, Y; Kobayashi, A; Mizukami, H; Nakazato, K; Noji, H; Ogawa, K; Ohkawara, H; Saitoh, S; Shichishima-Nakamura, A; Suzuki, H; Takahashi, H; Takeishi, Y; Yokokawa, T; Yoshihisa, A, 2013) |
| "As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide." | 1.36 | Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. ( de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, T | 1 |
| Ogo, T | 1 |
| Tahara, N | 1 |
| Fukui, S | 1 |
| Tsuji, A | 1 |
| Ueda, J | 1 |
| Fukumoto, Y | 1 |
| Nakanishi, N | 1 |
| Ogawa, H | 1 |
| Yasuda, S | 1 |
| Yokokawa, T | 1 |
| Nakazato, K | 1 |
| Kanno, Y | 1 |
| Mizukami, H | 1 |
| Kobayashi, A | 1 |
| Yoshihisa, A | 1 |
| Takahashi, H | 1 |
| Shichishima-Nakamura, A | 1 |
| Ohkawara, H | 1 |
| Noji, H | 1 |
| Suzuki, H | 1 |
| Saitoh, S | 1 |
| Ogawa, K | 1 |
| Hisa, S | 1 |
| Takeishi, Y | 1 |
| Tamura, S | 1 |
| Koyama, A | 1 |
| Shiotani, C | 1 |
| Kurihara, T | 1 |
| Nishikawa, A | 1 |
| Okamoto, Y | 1 |
| Fujimoto, T | 1 |
| Huls, G | 1 |
| Mulder, AB | 1 |
| Rosati, S | 1 |
| van de Loosdrecht, AA | 1 |
| Vellenga, E | 1 |
| de Wolf, JT | 1 |
| Li, J | 1 |
| Zhou, DB | 1 |
| Younis, TH | 1 |
| Alam, A | 1 |
| Paplham, P | 1 |
| Spangenthal, E | 1 |
| McCarthy, P | 1 |
| Hattori, Y | 1 |
| Shimoda, M | 1 |
| Okamoto, S | 1 |
| Satoh, T | 1 |
| Kakimoto, T | 1 |
| Ikeda, Y | 1 |
| Antonioli, E | 1 |
| Nozzoli, C | 1 |
| Gianfaldoni, G | 1 |
| Mannelli, F | 1 |
| Rossi, S | 1 |
| Betti, S | 1 |
| Bernardeschi, P | 1 |
| Fiorentini, G | 1 |
| Bosi, A | 1 |
| Lafaras, C | 1 |
| Mandala, E | 1 |
| Verrou, E | 1 |
| Platogiannis, D | 1 |
| Barbetakis, N | 1 |
| Bischiniotis, T | 1 |
| Zervas, K | 1 |
| Aschenbrenner, R | 1 |
| Herken, H | 1 |
1 review available for thalidomide and Hypertension, Pulmonary
| Article | Year |
|---|---|
New advances in the diagnosis and treatment of POEMS syndrome.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromo | 2013 |
10 other studies available for thalidomide and Hypertension, Pulmonary
| Article | Year |
|---|---|
Thalidomide for Hereditary Hemorrhagic Telangiectasia With Pulmonary Arterial Hypertension.
Topics: Adolescent; Adult; Blood Transfusion; Echocardiography; Electrocardiography; Fatal Outcome; Female; | 2018 |
Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome.
Topics: Aged; Dexamethasone; Diuretics; Drug Resistance; Edema; Furosemide; Heart Failure; Humans; Hypertens | 2013 |
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Huma | 2014 |
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Aged, 80 and over; Anabolic Agents; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents | 2010 |
Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma.
Topics: Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peri | 2003 |
Pulmonary hypertension and thalidomide therapy in multiple myeloma.
Topics: Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Middle Aged; Multiple Myeloma; Thalidomide | 2005 |
Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Female; Humans; Hypertension, Pulmonary; Middle Aged; Multiple Myeloma; Neo | 2005 |
Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dexamethasone; Echocardiography; Female; Heart Dis | 2008 |
[The doctor's responsibility and risk in the prescribing of drugs].
Topics: Adult; Amphetamine; Appetite Depressants; Drug and Narcotic Control; Drug Industry; Drug Packaging; | 1973 |
[Evaluation of the therapeutical range of drugs].
Topics: Adolescent; Adult; Appetite Depressants; Child; Chloramphenicol; Drug and Narcotic Control; Drug Eva | 1974 |